Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | 27.22 |
|---|---|
| High | 27.22 |
| Low | 27.22 |
| Bid | 27.44 |
| Offer | 27.64 |
| Previous close | 27.22 |
| Average volume | -- |
|---|---|
| Shares outstanding | 93.21m |
| Free float | 90.59m |
| P/E (TTM) | -- |
| Market cap | 472.59m USD |
| EPS (TTM) | -4.34 USD |
Data delayed at least 15 minutes, as of Jan 09 2020.
More ▼
Announcements
- Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
- Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
- Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
- Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
- Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
- Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
- Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
- Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
- Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
- New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
More ▼
